Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.

Abstract: A cotton molecular breeding method includes (1) obtaining a chr.7 single QTL segment substitution line with high fiber strength, and (2) using the obtained chr.7 single QTL segment substitution line as a non-recurrent parent () to cross with a recurrent parent (?) to obtain an F1 generation. Then (3) the F1 generation is back-crossed with the recurrent parent to obtain a BC1F1 generation, and (4) plants of the BC1F1 generation are screened for plants carrying the chr.7 single QTL segment, and then the screened plants are back-crossed with the recurrent parent for 2-4 times to obtain a BCnF1 generation. The method also includes (5) screening plants of the BCnF1 generation for plants carrying the chr.7 single QTL segment, and selfing the screened plants for 1-3 times to obtain a bred line BCnFm having the high cotton fiber strength.

Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.

Abstract: A cotton molecular breeding method includes (1) obtaining a chr.7 single QTL segment substitution line with high fiber strength, and (2) using the obtained chr.7 single QTL segment substitution line as a non-recurrent parent () to cross with a recurrent parent (?) to obtain an F1 generation. Then (3) the F1 generation is back-crossed with the recurrent parent to obtain a BC1F1 generation, and (4) plants of the BC1F1 generation are screened for plants carrying the chr.7 single QTL segment, and then the screened plants are back-crossed with the recurrent parent for 2-4 times to obtain a BCnF1 generation. The method also includes (5) screening plants of the BCnF1 generation for plants carrying the chr.7 single QTL segment, and selfing the screened plants for 1-3 times to obtain a bred line BCnFm having the high cotton fiber strength.

Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.

Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.

Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.

Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.

Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.

Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.

Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.

Abstract: The present invention discloses compound 2?,3?,5?-trihydroxy-androst-6-one, having the structure of formula (I). The present invention also discloses a plurality of methods for preparing the compound and a use of the compound.

Abstract: Disclosed is the use of 5?-androstane-3?,5,6?-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord ischemia or hypoxia and has no obvious toxic reaction within effective dose thereof.

Abstract: A 5?-androstane-3?,5,6?-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-?-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-?-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-?-cyclodextrin solution, 5?-androstane-3?,5,6?-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection. Drying the filtrate yields a solid for injection.

Abstract: A 5?-androstane-3?,5,6?-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-?-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-?-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-?-cyclodextrin solution, 5?-androstane-3?,5,6?-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection. Drying the filtrate yields a solid for injection.

Abstract: The present invention discloses compound 2?,3?,5?-trihydroxy-androst-6-one, having the structure of formula (I). The present invention also discloses a plurality of methods for preparing the compound and a use of the compound.

Abstract: A 5?-androstane-3?,5,6?-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-?-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-?-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-?-cyclodextrin solution, 5?-androstane-3?,5,6?-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection, Drying the filtrate yields a solid for injection.

Abstract: The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5?-androstane-3?,5,6?-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2? values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.

Abstract: Disclosed is the use of 5?-androstane-3?,5,6?-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord ischemia or hypoxia and has no obvious toxic reaction within effective dose thereof.

Abstract: Disclosed is the use of 5?-androstane(alkyl)-3?,5,6?-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord ischemia or hypoxia and has no obvious toxic reaction within effective dose thereof.